Skip to main content
. Author manuscript; available in PMC: 2020 Jul 20.
Published in final edited form as: Nat Immunol. 2020 Jan 20;21(2):178–185. doi: 10.1038/s41590-019-0578-8

Figure 3. MR1 is the cancer cell expressed target of MC.7.G5.

Figure 3

(a) Recognition of melanoma MM909.24 was reduced in the presence of MR1 blocking antibody (Ab). MHCI and II Abs were used as negative controls. Overnight activation and TNF ELISA. (b) Removal of MR1 expression (CRISPR/Cas9) from cancer cell lines prevented MC.7.G5 mediated recognition and killing. Overnight activation and TNF ELISA or chromium release cytotoxicity assay. (c) Lentiviral overexpression (+) of MR1 in poor targets of MC.7.G5 improved target cell killing by MC.7.G5. Chromium release cytotoxicity assay. (d) Lentiviral expression of MR1 in MR1-/- cells restores activation of MC.7.G5. TNF ELISA. Conditions performed in duplicate. Bars depict the mean.